Recently published papers: therapies failed, disputed, and beneficent

Area of Science:

• Critical Care Medicine
• Pulmonary Medicine
• Cardiology

Background:

• Drotrecogin alpha (activated) was once a promising therapy for acute respiratory distress syndrome (ARDS).
• Recent evidence suggests potential safety concerns and questions its overall benefit in ARDS management.
• Controversy exists regarding its efficacy and risk profile.

Purpose of the Study:

• To evaluate the current evidence on drotrecogin alpha (activated) for ARDS.
• To discuss the safety profile of drotrecogin alpha (activated).
• To review other critical care topics including postoperative atrial fibrillation, hypothermia after cardiac arrest, and renal replacement therapy.

Main Methods:

• Meta-analysis of existing studies on drotrecogin alpha (activated).
• Review of recent publications on drotrecogin alpha (activated) safety.
• Literature review of other critical care interventions.

Main Results:

• A recent meta-analysis indicates diminished efficacy for drotrecogin alpha (activated) in ARDS.
• Two new papers highlight ongoing safety concerns associated with drotrecogin alpha (activated).
• The review also touches upon the utility of steroids for preventing postoperative atrial fibrillation, the success of post-cardiac arrest hypothermia, and choices in intensive care unit renal replacement therapy.

Conclusions:

• Drotrecogin alpha (activated) is unlikely to be a viable therapy for ARDS.
• Further independent trials are warranted to definitively assess the safety and efficacy of drotrecogin alpha (activated).
• Optimal management strategies for ARDS and other critical care conditions require ongoing investigation.